SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal CancerSPARKLE
Status:
RECRUITING
Trial end date:
2027-11-30
Target enrollment:
Participant gender:
Summary
This is a prospective study to delve into the therapeutic benefits of combining stereotactic body radiation therapy (SBRT) with PD-1 monoclonal antibody treatment for patients with unresectable locally recurrent rectal cancer (ULRRC). Our aim is to ascertain the safety of this approach and to offer robust, evidence-based medical guidance for the management of ULRRC using this innovative combination therapy.
Researchers will combine SBRT with PD-1 for ULRRC to see if this treatment can provide a benefit of survival.
Participants will:
1. Receive chemotherapy combined with PD-1 therapy for 1 cycle SBRT treatment Chemotherapy combined with PD-1 therapy for 3-6 cycles (assessment 6 weeks after SBRT treatment) Surgery/Maintenance therapy.
2. Visit the clinic once every 3 months for checkups and tests
Phase:
PHASE2
Details
Lead Sponsor:
Sixth Affiliated Hospital, Sun Yat-sen University
Collaborators:
Fudan University Shenzhen People's Hospital Sun Yat-sen University Yunnan Cancer Hospital